Table 2 General characteristics of the included studies
Study Year | Study design | Population | Country | Sex (female %) | Age (y) | N | Duration (Ma) | |
|---|---|---|---|---|---|---|---|---|
Anticholinergicdrug use and peripheral effects | Thomson WM. 1993 | Cross-sectional study | Nursing home residents and geriatric hospital residents | New Zealand | 60% | 82.5 ± 2.4𝜹 | 359 | – |
Katz IR. 1988 | Cross-sectional study | Congregate Housing population | United States | 33% | 83.2 ± 5.8𝜹 | 53 | – | |
Ness J. 2006 | Prospective cohort study | Community-dwelling patients | United States | 2.1% | 74.3 | 532 | 3 | |
Desoutter A. 2012 | Cross-sectional study | Long term geriatric ward | France | no data | 84.6 ± 8.4𝜹 | 769 | – | |
Anticholinergic burden and peripheral effects | Rudolph JL. 2008 | Retrospective Cohort study | Community-dwelling patients | United States | 3% | 78.7 ± 5.3𝜹 | 132 | 9 |
Prospective Cohort study | 0% | 71.5 ± 11.6𝜹 | 117 | 10 | ||||
Kersten H. 2012 | Cross-sectional study | Nursing home residents | Norway | 79.3% | > 73 | 87 | – | |
Kersten H. 2013 | Randomized Controlled Trial | Nursing home residents | Norway | 79.3% | > 73 | 87 | 2 | |
Tiisanoja A. 2017 | Cross-sectional study | Community-dwelling patients | Finland | 73.6% | 79.6 ± 3.7𝜹 | 152 | – | |
Inkeri NM. 2019 | Cross-sectional study | Community-dwelling patients | Finland | 50.9% | > 65 | 1.084 | – | |
Lavrador M. 2021 | Case control Study | Patients admitted in Internal Medicine wards | Portugal | 50 | 81.7 ± 7.8 𝜹 | 250 | 12 |